DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is listed today as DiaMedica Therapeutics Inc. : market value, financials and filings are on its company page.
Funding rounds 0 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
Funding rounds of DiaMedica Therapeutics Inc. Month Raised Raise Size Investors Sold Filing Jul 2025 $30 M Private placement after listing $10 to $50 million 14
DiaMedica Therapeutics Inc.: Private sale, Jul 2025 × Investors in this round 14 investors had bought by the notice of Jul 25, 2025: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Canada (Federal Level) People named in the notice David J. Wambeke · Executive Officer Lorianne Masuoka · Executive Officer Rick Pauls · Executive Officer, Director Scott Kellen · Executive Officer Charles P. Semba · Director Daniel T. O'Connor · Director James T. Parsons · Director Michael R. Giuffre · Director Richard R. Kuntz · Director Tanya N. Lewis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Jul 25, 2025. Read the notice at the SEC .
equity SEC Jun 2024 $12 M Private placement after listing $10 to $50 million 10
DiaMedica Therapeutics Inc.: Private sale, Jun 2024 × Investors in this round 10 investors had bought by the notice of Jul 2, 2024: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $12 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Canada (Federal Level) People named in the notice David J. Wambeke · Executive Officer Lorianne Masuoka · Executive Officer Rick Pauls · Executive Officer, Director Scott Kellen · Executive Officer Charles P. Semba · Director James T. Parsons · Director R. Michael Giuffre · Director Richard D. Pilnik · Director Richard Michael Kuntz · Director Tanya N. Lewis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Jul 2, 2024. Read the notice at the SEC .
equity SEC Jun 2023 $38 M Private placement after listing $10 to $50 million 34
DiaMedica Therapeutics Inc.: Private sale, Jun 2023 × Investors in this round 34 investors had bought by the notice of Jun 27, 2023: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $38 M of $38 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $845,849
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Canada (Federal Level) People named in the notice David J. Wambeke · Executive Officer Dominic Cundari · Executive Officer Julie Daves · Executive Officer Kirsten Gruis · Executive Officer Rick Pauls · Executive Officer, Director Scott Kellen · Executive Officer Charles P. Semba · Director James T. Parsons · Director R. Michael Giuffre · Director Richard D. Pilnik · Director Richard P. Kuntz · Director Tanya N. Lewis · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, Minnesota Sold in CA, CT, FL, KY, MN, NY Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Jun 27, 2023. Read the notice at the SEC .
equity SEC Sep 2021 $30 M Private placement after listing $10 to $50 million 10
DiaMedica Therapeutics Inc.: Private sale, Sep 2021 × Investors in this round 10 investors had bought by the notice of Oct 6, 2021: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Canada (Federal Level) People named in the notice Harry W. Alcorn Jr. · Executive Officer Rick Pauls · Executive Officer, Director Scott Kellen · Executive Officer Sydney Gilman · Executive Officer Amy L. Burroughs · Director Charles P. Semba · Director James T. Parsons · Director R. Michael Giuffre · Director Richard D. Pilnik · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Scott Kellen, Chief Financial Officer and Secretary. Newest notice filed Oct 6, 2021. Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
DiaMedica Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).
SEC Form D · Jul 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2025
No products or services of DiaMedica Therapeutics Inc. are on record.
No investor of DiaMedica Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today Institutions holding DiaMedica Therapeutics Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by DiaMedica Therapeutics Inc. Name Role Named in David J. Wambeke Executive officer Jul 2025 Lorianne Masuoka Executive officer Jul 2025 Rick Pauls Executive officer Jul 2025 Scott Kellen Executive officer Jul 2025 Dominic Cundari Executive officer Jun 2023 Julie Daves Executive officer Jun 2023 Kirsten Gruis Executive officer Jun 2023 Harry W. Alcorn Jr. Executive officer Oct 2021 Sydney Gilman Executive officer Oct 2021 Charles P. Semba Director Jul 2025 Daniel T. O'Connor Director Jul 2025 James T. Parsons Director Jul 2025 Michael R. Giuffre Director Jul 2025 Richard R. Kuntz Director Jul 2025 Rick Pauls Director Jul 2025 Tanya N. Lewis Director Jul 2025 R. Michael Giuffre Director Jul 2024 Richard D. Pilnik Director Jul 2024 Richard Michael Kuntz Director Jul 2024 Richard P. Kuntz Director Jun 2023 Amy L. Burroughs Director Oct 2021
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.